(0.06%) 5 472.40 points
(0.10%) 39 150 points
(0.34%) 17 778 points
(-0.21%) $80.66
(-3.66%) $2.66
(-0.79%) $2 312.50
(0.16%) $28.92
(3.51%) $1 021.00
(0.29%) $0.936
(0.71%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors...
Stats | |
---|---|
今日成交量 | 0 |
平均成交量 | 2.11M |
市值 | 1.83B |
EPS | $-0.400 ( Q1 | 2024-05-07 ) |
下一个收益日期 | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-15.39 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00500 (0.02%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-04 | Bitetti Teresa Marie | Sell | 34 000 | Stock Option (Right to Buy) |
2024-06-04 | Gannon Steven | Sell | 56 400 | Common Stock |
2024-06-04 | Gannon Steven | Sell | 141 011 | Stock Option (Right to Buy) |
2024-06-04 | Gannon Steven | Sell | 30 000 | Stock Option (Right to Buy) |
2024-06-04 | Gannon Steven | Sell | 17 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
-67.50 |
Last 97 transactions |
Buy: 3 027 300 | Sell: 8 744 008 |
音量 相关性
Fusion Pharmaceuticals 相关性 - 货币/商品
Fusion Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $2.07M |
毛利润: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2023 |
营收: | $2.07M |
毛利润: | $723 000 (34.96 %) |
EPS: | $-1.450 |
FY | 2022 |
营收: | $1.46M |
毛利润: | $-57.43M (-3 931.14 %) |
EPS: | $-2.00 |
FY | 2021 |
营收: | $1.44M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.884 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company has a strategic collaboration agreement with AstraZeneca UK Limited to jointly discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。